Somatostatin receptor expression in thyroid disease

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Somatostatin analogues are established treatments for acromegaly and neuroendocrine tumors.
• The expression and therapeutic potential of somatostatin receptors (SSTRs) in thyroid disease remain unexplored.
• Understanding SSTR expression is crucial for developing targeted therapies for thyroid disorders.

Purpose of the Study:

• To evaluate the expression of somatostatin (SST) and somatostatin receptors (SSTR1-5) in normal and diseased thyroid tissues.
• To investigate the potential of SSTRs as therapeutic targets for novel somatostatin analogue treatments in thyroid conditions.

Main Methods:

• Analysis of 67 thyroid tissue specimens, including normal thyroids, differentiated thyroid carcinomas, follicular adenomas, multinodular goitres, Graves' disease, and Hashimoto's thyroiditis.
• Immunohistochemical staining for SST and SSTR1-5.
• Double-blinded observer assessment of receptor positivity and intensity.

Main Results:

• SSTRs 1, 3, 4, and 5 were highly expressed in normal thyroid tissue.
• SSTR2a and SSTR2b were absent in normal tissue but present in benign and malignant thyroid conditions (P < 0.02).
• SSTR2b was the most common receptor in all pathological subtypes, while SSTR5 was frequently expressed in differentiated thyroid cancer.

Conclusions:

• SSTRs 1, 3, 4, and 5 are widely expressed across normal, benign, and malignant thyroid tissues.
• The presence of SSTR2 in thyroid pathologies, contrasting with its absence in normal tissue, highlights its potential as a targeted therapeutic focus.
• Targeted SSTR2-based therapies may offer a promising new treatment avenue for various thyroid diseases.